Lotan Y - Search Results

1

Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.

Durinck S, Stawiski EW, Pavía-Jiménez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, Chen YJ, Saleem S, Chaudhuri S, Heldens S, Jackson M, Peña-Llopis S, Guillory J, Toy K, Ha C, Harris CJ, Holloman E, Hill HM, Stinson J, Rivers CS, Janakiraman V, Wang W, Kinch LN, Grishin NV, Haverty PM, Chow B, Gehring JS, Reeder J, Pau G, Wu TD, Margulis V, Lotan Y, Sagalowsky A, Pedrosa I, de Sauvage FJ, Brugarolas J, Seshagiri S. Durinck S, et al. Among authors: lotan y. Nat Genet. 2015 Jan;47(1):13-21. doi: 10.1038/ng.3146. Epub 2014 Nov 17. Nat Genet. 2015. PMID: 25401301 Free PMC article.

2

Histopathology of surgically managed renal tumors: analysis of a contemporary series.

Duchene DA, Lotan Y, Cadeddu JA, Sagalowsky AI, Koeneman KS. Duchene DA, et al. Among authors: lotan y. Urology. 2003 Nov;62(5):827-30. doi: 10.1016/s0090-4295(03)00658-7. Urology. 2003. PMID: 14624902 Review.

3

The effects of radio frequency ablation on renal function and blood pressure.

Johnson DB, Taylor GD, Lotan Y, Sagalowsky AI, Koenemann KS, Cadeddu JA. Johnson DB, et al. Among authors: lotan y. J Urol. 2003 Dec;170(6 Pt 1):2234-6. doi: 10.1097/01.ju.0000096265.22657.e8. J Urol. 2003. PMID: 14634386

4

Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy.

Khoddami SM, Shariat SF, Lotan Y, Saboorian H, McConnell JD, Sagalowsky AI, Roehrborn CG, Koeneman KS. Khoddami SM, et al. Among authors: lotan y. BJU Int. 2004 Jul;94(1):42-6. doi: 10.1111/j.1464-410X.2004.04898.x. BJU Int. 2004. PMID: 15217428

5

Changing management of organ-confined renal masses.

Lotan Y, Duchene DA, Cadeddu JA, Sagalowsky AI, Koeneman KS. Lotan Y, et al. J Endourol. 2004 Apr;18(3):263-8. doi: 10.1089/089277904773582877. J Endourol. 2004. PMID: 15225392

6

Application of novel hemostatic agent during laparoscopic partial nephrectomy.

Margulis V, Matsumoto ED, Svatek R, Kabbani W, Cadeddu JA, Lotan Y. Margulis V, et al. Among authors: lotan y. J Urol. 2005 Aug;174(2):761-4. doi: 10.1097/01.ju.0000164727.53999.fe. J Urol. 2005. PMID: 16006972

7

Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.

Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, Shariat SF. Svatek RS, et al. Among authors: lotan y. Cancer. 2006 Apr 15;106(8):1701-7. doi: 10.1002/cncr.21795. Cancer. 2006. PMID: 16541433 Free article.

8

Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy.

Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Shariat SF, et al. Among authors: lotan y. Eur Urol. 2007 Jan;51(1):137-49; discussion 149-51. doi: 10.1016/j.eururo.2006.05.021. Epub 2006 Jun 8. Eur Urol. 2007. PMID: 16793197

9

Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis.

Svatek RS, Sagalowsky AI, Lotan Y. Svatek RS, et al. Among authors: lotan y. Urol Oncol. 2006 Jul-Aug;24(4):338-43. doi: 10.1016/j.urolonc.2005.11.025. Urol Oncol. 2006. PMID: 16818188

10

Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.

Lotan Y, Svatek RS, Sagalowsky AI. Lotan Y, et al. Cancer. 2006 Sep 1;107(5):982-90. doi: 10.1002/cncr.22084. Cancer. 2006. PMID: 16862567 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

771 results

Search Page

Filters